Candesartan for Migraine Prevention:

Summary

The main objective of this study is to see whether the favorable preventative effect of candesartan 16 mg per day in episodic migraine, that was found previously in two smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) also a smaller dose of 8 mg is effective, and 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose.

Timeline

Start

2021-04-09

Primary completion

2024-04-12

Completion

2024-08-08

Outcome

Met primary endpoint

paper difference between groups -1·22 [95% CI -1·75 to -0·70]; p<0·0001 PMID 40975098 ↗

paper the reduction in migraine days was 2·04 days (95% CI 1·65-2·41 p<0·0001) in the candesartan 16 mg group PMID 40975098 ↗

Publications

• Oie LR, Wergeland T, Salvesen O, Gravdahl GRB, Aschehoug I, Gulati S, Bj Rk MH, Lundqvist C, Alstadhaug KBR, Winsvold BS, Aamodt AH, Larsen IC, B E MG, Braschinsky M, Muller B, Vetvik KGT, Muller KI, Aaseth K, Khanevski AN, Ovrevik AB, Vegrim HM, Lindroos J, Eid K, Engstrand H, Bezgal B, Larsen MB, Osthus JHG, Stovner LJ, Tronvik E. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2025 Oct;24(10):817-827. doi: 10.1016/S1474-4422(25)00269-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Candesartan	Unknown	8 mg	Oral
Subject	Candesartan	Unknown	16 mg	Oral

Indications